Gilead Sciences Extends Tender Offer for Arcellx Shares to April 14, 2026

Gilead Sciences has announced an extension of its tender offer to acquire all outstanding shares of Arcellx, Inc., a clinical-stage biotechnology company. The offer, originally set to expire on March 31, 2026, will now remain open until April 14, 2026, unless further extended or terminated under the terms of the agreement between the two companies.

The tender offer was initially launched as part of Gilead’s strategy to expand its portfolio in cell therapy and immuno-oncology. According to the announcement, as of the original expiration date, a significant portion of Arcellx’s outstanding shares had already been tendered but did not yet meet the conditions required for completion. The extension aims to provide additional time for shareholders who have not yet participated in the offer. Both companies have stated that they remain committed to finalizing the transaction and advancing their shared goals in developing innovative therapies for patients with unmet medical needs.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 1, 2026

Author

GOAI